# STA-4783 in Combination With Paclitaxel and Carboplatin for the Treatment of Chemotherapy Naive Patients With Stage IIIB/IV Non Small Cell Lung Cancer (NSCLC)

> **NCT00088088** · PHASE1,PHASE2 · COMPLETED · sponsor: **Synta Pharmaceuticals Corp.** · enrollment: 86 (—)

## Conditions studied

- Stage IIIB Non-Small Cell Lung Cancer
- Stage IV Non-Small Cell Lung Cancer

## Interventions

- **DRUG:** Paclitaxel
- **DRUG:** Carboplatin
- **DRUG:** STA 4783

## Key facts

- **NCT ID:** NCT00088088
- **Lead sponsor:** Synta Pharmaceuticals Corp.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-03
- **Primary completion:** —
- **Final completion:** 2005-03
- **Target enrollment:** 86 (—)
- **Last updated:** 2008-12-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00088088

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00088088, "STA-4783 in Combination With Paclitaxel and Carboplatin for the Treatment of Chemotherapy Naive Patients With Stage IIIB/IV Non Small Cell Lung Cancer (NSCLC)". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT00088088. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*